1[1]Schoemaker H,Claustre Y,Fage D,et al.Neurochemical character- ristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.J Pharmacol Exp Ther,1997,280(1):83
2[2]Cudennec A,Fage D,Benavides J,et al.Effects of amisulpride,an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors,on integrated functional cerebral activity in the rat.Brain Rec,1997,768(1-2):257
3[3]Trichard C,Paillere-Martinot ML,Attar-Levy D,et al.Binding of antipsychotic drugs to cortical 5-HT2A receptors:a PET sutdy of chlorpromazine,clozapine,and amisulpride in schizophrenic patients.Am J Psychiatry,1998,155(4):505
4[4]Hamon-Vilcot B,Chaufour S,Deschamps C,et al.Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers.Eur J Clin Pharmacol,1998,54(5):405
5[5]Chabannes JP,Pelissolo A,Farah S,et al.Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses.Encephale,1998,24(4):386
6[6]Puech A,Fleurot O,Rein W.Amisulpride,and atypical antipsychotic,in the treatment of acute episodes of schizophrenia:a dose-ranging study vs haloperidol.Acta Psychiatr Scand,1998,98(1):66
7[7]Wetzel H,Grunder G,Hillert A,et al.Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology-a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist.Psychopharmacology(Berl),1998,137(3):223
8[8]Rein W,Turjanski S.Clinical update on amisulpride in deficit schizophrenia.Int Clin Psychopharmacol,1997,12(Suppl)2:19
9[9]Danion JM, Rein W, Fleurot O. Improvements of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiatry, 1999, 156(4):610
10[10]Ravizza L.Amisulpride in medium-term treatment of dysthymia a six-month,double blind safety study versus amitriptyline.J psychopharmacol,1999,13(3):248
